{"title":"研制理想安眠药的进展。","authors":"Reynold Spector","doi":"10.1016/j.amjmed.2024.11.019","DOIUrl":null,"url":null,"abstract":"<p><p>Thirty percent of Americans report insomnia. After eliminating obvious causes, the best therapy for insomnia is cognitive behavioral therapy, but this is not widely available. However, all the known oral sleeping aides are generally unsatisfactory. Recently, a new class of safe, nonaddicting, mechanism-based hypocretin blockers have been developed. Herein we review the information not only for insomnia but also for narcolepsy.</p>","PeriodicalId":50807,"journal":{"name":"American Journal of Medicine","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Progress Toward an Ideal Sleeping Pill.\",\"authors\":\"Reynold Spector\",\"doi\":\"10.1016/j.amjmed.2024.11.019\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Thirty percent of Americans report insomnia. After eliminating obvious causes, the best therapy for insomnia is cognitive behavioral therapy, but this is not widely available. However, all the known oral sleeping aides are generally unsatisfactory. Recently, a new class of safe, nonaddicting, mechanism-based hypocretin blockers have been developed. Herein we review the information not only for insomnia but also for narcolepsy.</p>\",\"PeriodicalId\":50807,\"journal\":{\"name\":\"American Journal of Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-12-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.amjmed.2024.11.019\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.amjmed.2024.11.019","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
Thirty percent of Americans report insomnia. After eliminating obvious causes, the best therapy for insomnia is cognitive behavioral therapy, but this is not widely available. However, all the known oral sleeping aides are generally unsatisfactory. Recently, a new class of safe, nonaddicting, mechanism-based hypocretin blockers have been developed. Herein we review the information not only for insomnia but also for narcolepsy.
期刊介绍：
The American Journal of Medicine - "The Green Journal" - publishes original clinical research of interest to physicians in internal medicine, both in academia and community-based practice. AJM is the official journal of the Alliance for Academic Internal Medicine, a prestigious group comprising internal medicine department chairs at more than 125 medical schools across the U.S. Each issue carries useful reviews as well as seminal articles of immediate interest to the practicing physician, including peer-reviewed, original scientific studies that have direct clinical significance and position papers on health care issues, medical education, and public policy.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
